Longaeva Partners »

Entrada Therapeutics shares owned by Longaeva Partners

Quarter-by-quarter ownership of Entrada Therapeutics (TRDA) shares owned by Longaeva Partners from 13F filings

Historical chart of Longaeva Partners investment in Entrada Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Entrada Therapeutics held by Longaeva Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Entrada Therapeutics by Longaeva Partners

Quarter filed Position value Share count Share price at filing
2026-03-31 $2.6M 205k 12.62

More positions owned by Longaeva Partners

Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)
Boston Scientific Corporation Call Option (BSX)
Bank of America Corporation (BAC)
NVIDIA Corporation Call Option (NVDA)
PNC Financial Services (PNC)
Key (KEY)
Goldman Sachs (GS)
Morgan Stanley Com New (MS)
Minimed Group
Citizens Financial (CFG)
Evercore Class A (EVR)
Mastercard Incorporated Cl A (MA)
Msci (MSCI)
S&p Global (SPGI)
Us Bancorp Com New (USB)

View all positions for Longaeva Partners

Top funds holding Entrada Therapeutics

Baker Bros. Advisors
5AM Venture Management
BlackRock
TCG Crossover Management
Vanguard Group
Vanguard Capital Management
Wellington Management Company
StepStone
Geode Capital Management
Millennium Management
State Street Corporation
Jones Hill Capital
Jacobs Levy Equity Management
Acadian Asset Management
Dimensional Fund Advisors

View all funds holding Entrada Therapeutics